Ameriprise’s Immune Design Corp. IMDZ Stock Holding History

Ameriprise’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-22,105	Closed	-$73K	–	3777
2018 Q1	$73K	Buy	+22,105	New	+$78.3K	﹤0.01%	3573

Other funds holding IMDZ

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise's IMDZ Position: Q2 2018 in Review

Ameriprise sold out of Immune Design Corp. (IMDZ) in Q2 2018, closing a stake of 22,105 shares — an estimated $73K sold.

Ameriprise first reported a position in IMDZ in Q1 2018 and held it in 1 quarter. The position peaked at $73K in Q1 2018. 80 funds tracked by Wall St. Rank hold IMDZ as of Q2 2018.

Ameriprise reported no remaining Immune Design Corp. position as of Q2 2018 after selling out during the quarter.
Ameriprise sold 22,105 Immune Design Corp. shares in Q2 2018, an estimated $73K.
Ameriprise first reported a position in Immune Design Corp. in Q1 2018 and held it in 1 quarter.
Ameriprise's Immune Design Corp. position peaked at $73K in Q1 2018.
80 funds tracked by Wall St. Rank held Immune Design Corp. as of Q2 2018.

Based on Ameriprise's 13F filing for Q2 2018, filed 14 Aug 2018.